06.04.26 -- Contracting For AI In Clinical Trials

See late‑2025 policy actions, including international pricing agreements, new payment models, and global regulatory changes, while previewing key themes expected to shape 2026 health policy.

How does specialized knowledge compound over time into foresight, stronger execution, and more confident decision-making across the drug development lifecycle?

Regulators are no longer questioning whether AI belongs in clinical trials; however, they’re demanding a governed infrastructure that makes every AI-driven decision auditable and defensible.

Centralized submissions, greater transparency, and stronger patient protections reshape EU clinical trials, impacting timelines, costs, and strategies for sponsors and CROs.

Learn how leveraging a customs warehouse can streamline your supply chain, reduce VAT costs, and enhance global compliance and efficiency.

Experts share how Altasciences' integrated Preclinical/Clinical model results in fewer handoffs, greater continuity, and accelerated progress from the nonclinical phase to first-in-human trials.

Choosing a CRO requires sponsors to assess reliability, automation, GLP rigor, scientific engagement, pricing clarity, and capacity to find partners who deliver defensible data on real timelines.

Scale your biologic fill-finish from vials to autoinjectors without disruption. See how integrated device assembly capabilities support every clinical phase through commercialization.

See how experienced compounding support helps ensure study drugs are prepared accurately and consistently across administration routes, meeting cGMP requirements while supporting protocols.